Duvelisib

CHEMBL3039502 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
416.9 g/mol
LogP
4.1
Phase
4

A dual PI3K delta and gamma inhibitor used to treat chronic lymphocytic leukemia and follicular lymphoma in patients who have received prior therapy. It blocks signaling pathways that allow cancer cells to survive and proliferate.

Moleküler Ağırlık

416,9000 g/mol

LogP

4,10

TPSA

86,80 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1

InChI

InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1

Molecular Formula

C22H17ClN6O

HBD / HBA

2 / 5

Döndürülebilir Bağlar

4

Ağır Atomlar

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A dual PI3K delta and gamma inhibitor used to treat chronic lymphocytic leukemia and follicular lymphoma in patients who have received prior therapy. It blocks signaling pathways that allow cancer cells to survive and proliferate.

Yes, Duvelisib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3039502. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 50905713. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.